Godavari Biorefineries Limited (BSE: 544279 | NSE: GODAVARIB), through its clinical-stage biotech arm Sathgen Therapeutics, has been granted a patent by the China National Intellectual Property Administration (CNIPA) for its novel anti-cancer molecule – HYDROXY-1,4-NAPHTHALENEDIONE.
The patented molecule belongs to a new class of compounds that have shown strong inhibitory effects on cancer and cancer stem cells during in vitro studies. These compounds demonstrated notable efficacy against multiple types of cancer cells, including breast and prostate cancers.
“Our focus on original, high-quality science continues to guide our journey beyond green chemistry into life sciences,” said Dr Sangeeta Srivastava, Executive Director at Godavari Biorefineries. “This Chinese patent reinforces the promise of our lead molecule and the vital work of Sathgen Therapeutics in addressing critical medical needs.”
Godavari Biorefineries, a global exporter to over 20 countries, has steadily expanded its footprint into life sciences through Sathgen Therapeutics, which is advancing clinical research in cancer and antiviral therapies. With its lead molecule already in clinical trials and protected by global patents, the company is intensifying its focus on translational research tackling major health challenges.